ADCT Stock Analysis: Buy, Sell, or Hold?
ADCT - ADC Therapeutics SA
$3.17
-0.08 (-2.46%)
▼
5d:
-8.91%
30d:
-25.93%
90d:
-24.16%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 04, 2026
0d
Smart Money Accumulation
ADCT is down 7.1% this week, but smart money is accumulating calls. Top strike: $5 2026-07-17 with 321 OI. Call ratio: 96% View Scanner →
Strength: 8.1/10
Get Alerted When ADCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ADCT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ADCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ADCT is currently trading at $3.17, which is considered oversold relative to its 30-day fair value range of $3.48 to $4.10.
Technical Outlook: Technically, ADCT is showing sideways momentum. The price is currently testing key support at $3.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ADCT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.20 (+152.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADCT is showing sideways momentum. The price is currently testing key support at $3.13. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ADCT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.20 (+152.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.48 -
$4.10
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 152.3% below Wall St target ($8.20)
- CAUTION: 5-day price weakness (-8.9%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$3.48 -
$4.10
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.13
Resistance Level
$4.13
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.26
Wall Street Target
$8.20
(+152.3%)
Revenue Growth (YoY)
-9.5%
Profit Margin
-173.0%
Share & Embed Analysis
Last updated: May 18, 2026 4:24 PM ET
Data refreshes hourly during market hours. Next update: 5:24 PM
Data refreshes hourly during market hours. Next update: 5:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Redmile Group, Llc
SELL
2529491 shares
2026-04-02
Redmile Group, Llc
SELL
2634506 shares
2026-04-02
Redmile Group, Llc
SELL
162517 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$126 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 53 HOLD |
